SeraCare Announces Receipt of Delisting Notice from NASDAQ
March 21 2006 - 7:10PM
PR Newswire (US)
OCEANSIDE, Calif., March 21 /PRNewswire-FirstCall/ -- SeraCare Life
Sciences, Inc. (NASDAQ:SRLSENASDAQ:SRLS), today announced that it
has received notification from NASDAQ that the Panel has determined
to delist the Company's securities from NASDAQ, effective at the
open of business on Wednesday, March 22, 2006. As previously
reported, the Company requested a hearing before the NASDAQ Listing
Qualifications Panel to review NASDAQ's initial determination to
delist the Company's securities. This hearing was held on February
2, 2006. Subsequent to this hearing, the Company received two
additional Staff Determination Letters from NASDAQ regarding
delisting. The first of these two additional letters, dated
February 13, 2006, cited the Company's failure to timely complete
and file its quarterly report on Form 10-Q for the fiscal quarter
ended December 31, 2005. The second letter, dated March 15, 2006,
cited the Company's announcements contained in its current report
on Form 8-K, filed with the SEC on March 15, 2006, noting that
those matters raised significant public interest concerns under
Market Place Rule 4300 and served as an additional basis for
delisting the Company's securities from NASDAQ. Upon its delisting,
brokers or dealers may submit to the Pink Sheets, solely on behalf
of customers, quotations for the Company's common stock that
represent unsolicited indications of interest. The Company is
unable to predict when or if quotations for its common stock will
be included on the Pink Sheets or any other quotation service.
About SeraCare Life Sciences SeraCare Life Sciences Inc. is a
manufacturer and provider of biological products and services to
diagnostic, therapeutic, drug discovery, and research
organizations. The Company's offerings include plasma-based
therapeutic products, diagnostic products and reagents, cell
culture products, specialty plasmas, in vitro stabilizers, and the
SeraCare BioBank(TM), a proprietary database of medical information
and associated blood, plasma, DNA and RNA samples. Headquartered in
Oceanside, CA, SeraCare conducts business throughout the world. For
additional information about SeraCare Life Sciences Inc., please
visit the Company's web site at http://www.seracare.com/. Contact:
The Trout Group Tim Ryan, 212-477-9007x24 DATASOURCE: SeraCare Life
Sciences, Inc. CONTACT: Tim Ryan of The Trout Group,
+1-212-477-9007, ext. 24, or , for SeraCare Life Sciences, Inc. Web
site: http://www.seracare.com/
Copyright
Seracare Life Sciences (NASDAQ:SRLSE)
Historical Stock Chart
From Apr 2024 to May 2024
Seracare Life Sciences (NASDAQ:SRLSE)
Historical Stock Chart
From May 2023 to May 2024